Pancreatic cancer is where hope goes to die. The five-year survival rate hasn’t meaningfully budged in decades, and the frontline standard of care (gemcitabine plus nab-paclitaxel) buys patients a median of about 8-9 months. Every few years, someone announces a breakthrough. It rarely holds up.

So when Actuate Therapeutics publishes Phase 2 data in Nature Medicine showing their drug elraglusib nearly tripled one-year survival rates when added to that same chemo backbone, it’s worth paying close attention.

The numbers from the Actuate-1801 trial (286 previously untreated metastatic PDAC patients, randomized 2:1): the elraglusib combo produced median overall survival of 10.1 months versus 7.2 months for chemo alone. A 37% reduction in risk of death. And the 1-year survival gap is where it gets striking.

At 18 months, the separation gets even more dramatic: over 20% of elraglusib patients still alive versus 4% on chemo alone. In a disease where most patients don’t make it to their first birthday after diagnosis, that gap matters.

The mechanism is interesting too. Elraglusib is a GSK-3β inhibitor, which sounds like a generic kinase story until you look at the biopsy data. Treated patients showed a 7- to 40-fold increase in tumor-infiltrating cytotoxic immune cells (CD8+ T cells, NK cells) and a decrease in myeloid-derived suppressor cells. The drug is turning cold pancreatic tumors warm. That’s an immunomodulatory effect on top of the direct anti-tumor activity.

We covered the pancreatic cancer space yesterday with the RAS-targeted wave building across multiple companies. Elraglusib takes a completely different approach, going after the tumor’s immune evasion machinery rather than its oncogenic driver. Both angles are showing signs of life. For a disease that has resisted almost everything thrown at it, that’s something.

Actuate (NASDAQ: ACTU) has FDA Fast Track designation and plans to engage FDA and EMA on a registration pathway later this year. They’re also advancing elraglusib in pediatric Ewing sarcoma, where it’s shown early activity signals in refractory patients.